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Background: The inflammatory responses play a major role in the pathogenesis of acute myocardial infarction (MI).
Early inhibition of inflammation may improve post MI cardiac function. The aim of this study was to investigate the
effects of tacrolimus on cardiac function, hemodynamic parameters as well as histopathologic and
electrocardiographic changes in isoproterenol-induced myocardial infarction.
Methods: Male Wistar rats were randomly divided into six groups of control, isoproterenol alone, tacrolimus alone,
and isoproterenol plus tacrolimus (0.5, 1 and 2 mg/kg). Isoproterenol (100 mg/kg) was injected subcutaneously for
two consecutive days to induce myocardial infarction, and simultaneously tacrolimus was administered orally twice
a day for three days.
Results and conclusions: Administration of isoproterenol resulted in myocardial edema and necrosis as well as a
marked reduction in the left ventricular systolic pressure (LVSP), left ventricular contractility (LVdP/dtmax) and relaxation
(LVdP/dtmin) along with a severe elevation in left ventricular end-diastolic pressure (LVEDP). Isoproterenol also elevated
the ST-segment and suppressed the R-amplitude and R-R interval on ECG. It was found that all doses of tacrolimus
could amend the ECG pattern and ameliorated the isoproterenol induced disturbances in cardiac function. Acute and
short term treatment with tacrolimus at dose of 2 mg/kg significantly (P < 0.001) improved LVdP/dtmax from 2712 ± 82
in myocardial infarcted rats to 4592 ± 149 mmHg/sec. Similarly, tacrolimus lowered LVEDP from 17.6 ± 0.68 in MI group
to the value of 5.6 ± 0.22 mmHg (P < 0.001). Furthermore, tacrolimus was found to reduce malondialdehyde concentration
in serum and myocardium by 50-70% (P < 0.001).
The results of this study showed that acute treatment with tacrolimus, coincided with the occurrence of myocardial
infarction, strongly protected the myocardium against the isoproterenol-induced myocardial infarction; where this
might be due to the anti-inflammatory properties of tacrolimus.
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Cardiovascular disease (CVD), predominantly myocardial
infarction, is the leading cause of death worldwide [1,2].
Reductions in the myocardial blood flow due to the
coronary artery occlusion can considerably compromise
the energy metabolism. Coronary artery occlusion, only
as short as 5 minutes, can lead to oxidative stress and
then functional abnormalities of the myocardium that
persist up to 24–48 hours after reperfusion [3-5].* Correspondence: garjania2002@yahoo.com
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unless otherwise stated.The existing therapeutic approaches are designed to
reduce the myocardial necrosis and also amendment of
cardiac function after a myocardial infarction. Several
studies have shown that consecutive vigorous inflamma-
tory and immune reactions increases the generation of
cytokines and oxidative stress, recruits inflammatory and
T cells, and initiates the complement cascade [6,7]. The
inflammatory responses induced by myocardial ischemia
play a major role in the pathogenesis of acute myocardial
infarction (AMI). In addition, recent studies have demon-
strated that myocardial necrosis and subsequent oxidative
stress trigger a cytokine cascade initiated by Tumor
Necrosis Factor (TNF)-α. These inflammatory responsesal Ltd. This is an Open Access article distributed under the terms of the Creative
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eling after AMI [1,6,8], which lead to a progressive and
irreversible myocardial damage. One of the principal
interventions that exist for AMI is early inhibition of
the inflammatory cycle and thus achieves a better recovery
of the myocardium.
Tacrolimus (FK506) is a macrolide produced by the bac-
teria Streptomyces tsukubaensis. It is an immunosuppres-
sant mainly used in organ transplantation in order to
reduce the risk of graft rejection. Activation of T cells
by allogenic antigens in transplanted tissue increases
intracellular calcium concentration that contributes to
the calcium-calmodulin complex formation. Calcium-
calmodulin complex, in turn, activates calcineurin, a
crucial phosphatase for T cell signaling [9,10]. Tacrolimus
binding to the FK506 binding protein (FKBP), a respective
cytoplasmic receptor, inactivates calcineurin, thereby
the inflammatory response. FKBP is present in most
tissues, including the myocardium. In addition to the
anti-inflammatory effects of FK506-FKBP complex, it
plays a critical role in modulating myocardial calcium
homeostasis and rhythm regulation by stabilizing Rya-
nodine receptors [7,11]. The complex of FK506-FKBP
inhibits the phosphatase activity of calcineurin and the
calcium-dependent inflammatory responses. Moreover,
some experimental studies have revealed that tacrolimus
can effectively inhibit MAPK and PI3K-Akt signaling
pathways in various inflammatory diseases [7].
Isoproterenol (ISO) is a synthetic beta-adernoceptor
agonist and its subcutaneous injection induces irreversible
cellular damage and ultimately myocardial infarction in
rats. The acute hemodynamic and electrocardiographic
changes in isoproterenol induced myocardial infarction
resemble closely to those occurring in patients with myo-
cardial infarction [12]. Therefore, the rat model of iso-
proterenol induced myocardial infarction offers a reliable
non-invasive technique for studying the effects of various
potentially cardioprotective agents [13].
The aim of the present study was to investigate the
potential cardioprotective effects of tacrolimus on acute
heart remodeling, hemodynamic, electrocardiographic, and




Male albino Wistar rats weighing between 260 and 280 g
were used in the present study. The animals were housed
in standard polypropylene cages (six per cage) under a
12/12 h light/dark cycle at a constant temperature of
20 ± 1.8°C and ambient humidity of 50 ± 10%. The rats
were given food and water freely. This study was per-
formed in accordance with the Guide for the Care and Use
of Laboratory Animals of Tabriz University of MedicalSciences, Tabriz-Iran (National Institutes of Health publi-
cation No 85–23, revised 1985).
Induction of acute myocardial infarction
Isoproterenol (Sigma Co; USA) was dissolved in normal
saline and injected subcutaneously to rats (100 mg/kg)
for two consecutive days at an interval of 24 hours to
induce acute myocardial infarction. Animals were sacri-
ficed 48 hours after the first injection of isoproterenol [13].
Experimental protocol
The animals were randomly divided into six groups con-
sisting of six rats each. Rats in group1 (normal control) re-
ceived a subcutaneous injection of normal saline (0.5 ml)
and were left untreated for the entire experimental period.
Rats in group 2 (sham) were received an oral administra-
tion of tacrolimus (2 mg/kg; twice daily) for two consecu-
tive days and were subcutaneously injected with normal
saline. To induce myocardial infarction, rats in group 3
(MI control; ISO) were subcutaneously (SC) injected with
isoproterenol (100 mg/kg) dissolved in normal saline as a
vehicle (0.5 ml) for two consecutive days at an interval of
24 h. Rats in groups 4 to 6 were orally treated with tacroli-
mus at 0.5, 1 and 2 mg/kg twice daily. The treatment was
started immediately prior to induction of MI (SC injection
of isoproterenol) for the ensuing 2 days.
Hemodynamic measurements
About 24 to 48 hours after the last administration of drug,
the animals were anesthetized by the intraperitoneal injec-
tion of a mixture of ketamine (50 mg/kg), xylazine (30 mg/
kg), and acepromazine (20 mg/kg). When rats did not
respond to noxious stimuli, a standard limb lead (II) ob-
served constantly during the experimental period and any
changes in ECG pattern were documented. To observe the
hemodynamic parameters, a ventral midline skin incision
was made from the lower mandible posteriorly to the ster-
num (~3 cm) and the left common carotid artery was iso-
lated. The artery was temporary occluded toward the heart
using a dieffenbach serrefines clamp (Elcon; Germany).
Vannas micro iris scissors (Medi Plus; USA) was used to
make a tiny incision on the carotid artery. A polyethylene
cannula (Protex; OD 0.98 mm, ID 0.58 mm), coupled to a
pressure transducer (Powerlab system; AD Instruments,
Australia), was inserted into the artery for the recording
systemic arterial blood pressure. The mean arterial blood
pressure was calculated from the systolic and diastolic
blood pressure traces. To assess the cardiac left ven-
tricular function, a Mikro-Tip® catheter transducer (Millar
Instruments, INC) was inserted to the lumen of the left
ventricle. This helped to measure the left ventricular sys-
tolic pressure (LVSP), left ventricular end-diastolic pressure
(LVEDP), maximum and minimum rates of developed
left ventricular pressure (LVdP/dtmax and LVdP/dtmin
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left ventricular pressure (LVdP/dt/P). All the parameters
were continuously recorded using a Powerlab system (AD
Instruments, Australia) [14].
Tissue weights
Subsequent to hemodynamic measurements, the animals
were euthanized, the hearts were removed, weighed, and
histological examinations were done. The wet heart weight
to body weight ratio was calculated to assess the degree of
myocardial weight gain.
Determination of lipid peroxidation in serum and
myocardium
Malondialdehyde (MDA), a thiobarbiturate reactive sub-
stance, was measured as a marker for oxidative stress in
serum and myocardial homogenates using a method pre-
scribed by Satoh [15]. To prepare the homogenates, an-
other set of experiment (n = 6) including all groups was
repeated and 500 mg of heart tissues from apex were
homogenized in a ratio of 1:10 in 0.15% KCl by means
of a homogenizer. Consequently the homogenates were
centrifuged at 4 000 rpm at 4°C for 10 min. Then 3 mL
of phosphoric acid and 1 mL of TBA 0.67% were added
to 250 μL of supernatant of each homogenate to analyze
the MDA level in tissue samples. After addition of 3 mL
of n-Butanol to each sample, they heated in a water
bath for 40 min and the absorbance of MDA was mea-
sured spectrophotometrically. The lipid peroxidation level
expressed as nanomole MDA production per gram myo-
cardium and nonomole per milliliter serum.
Histopathological examination
The hearts were fixed in 10% buffered formalin. The heart
tissues were embedded in paraffin, sectioned at 5 μm, and
stained with hematoxylin and eosin (H&E) for histologic
evaluation and observed microscopically. Myocardial ne-
crosis and edematous were evaluated in each of the four
quadrants of the left ventricular cross section in each heart
in the zone lying within 1.5 mm of the ventricular endo-
cardium, using a morphometric point-counting procedure
[16]. Two persons graded the histopathological changes as
1, 2, 3, and 4 for low, moderate (focal myocyte damage or
small multifocal degeneration with slight degree of in-
flammation), high (extensive myofibrillar degeneration
and/or diffuse inflammatory process), and intensive (necro-
sis with diffuse inflammatory process) pathological changes,
respectively.
Measurements of serum TNF-α level by ELISA
The serum level of TNF-α was determined using an
enzyme-linked immunosorbent assay (ELISA) (Rat TNF-α,
IBL, Hamburg, Germany) according to the manufac-
ture’s instruction. Briefly, the samples were homogenizedor mixed in an ice-cold solution containing 50 mM Tris–
HCl, 150 mM NaCl, 5 mM Sodium Pyrophosphate (NaPPi),
50 mM NaF, 1 mM EDTA, 1 mM.
dithiothreitol (DTT), 0.1%SDS (w/v), 1% TXT-100
(v/v), and protease inhibitor cocktail (Roche, Mannheim,
Germany). The samples were then centrifuged twice at
10,000 (rpm) for 10 min at 4°C. The resulting supernatants
were used for assay. The concentration of the cytokines
was expressed as pg/ml of serum.
Statistics
Data were presented as mean ± SEM. One-way ANOVA
was used to make comparisons between the groups. If the
ANOVA analysis indicated significant differences, Student–
Newman–Keuls post test was employed to compare the
mean values between the treatment groups and the control.
Differences between the groups were considered significant
if P < 0.05.
Results
Effects of tacrolimus on electrocardiogram
The Lead II electrocardiograms obtained from animals
were shown in Figure 1. The rats were received tacrolimus
alone (sham) showed normal patterns of ECG, while the
rats treated with isoproterenol alone (MI group) demon-
strated significant changes in ECG pattern. The changes
included a marked elevation of ST segment from 95 ± 5.2
μv in control group to 194 ± 14.2 μv in ISO-treated group
(P < 0.001), and a reduction in R wave amplitude from
448 ± 27 μv in control group to 267 ± 15 μv in ISO-treated
group (P < 0.001) which both are indicative of myocardial
infarction (Figure 2). Oral treatment with tacrolimus at
doses of 0.5, 1 and 2 mg/kg significantly suppressed the
isoproterenol-induced ST-segment elevation from 194 ±
14.2 μv in ISO-treated group to 169 ± 12.7, 113 ± 8.4 and
121 ± 11 μv in tacrolimus-treated groups, respectively.
Furthermore, treatment with all doses of tacrolimus
resulted in a significant increase in the R-amplitude (P <
0.001) as compared to the rats treated with isoproterenol
alone (Figure 2).
Effects of tacrolimus on hemodynamic responses
The mean arterial pressure (MAP) was significantly de-
creased from 79.5 ± 1.78 mmHg in control group to 37 ±
1 mmHg in isoproterenol-treated group (P < 0.001; Table 1).
There was a significant increase in the mean arterial pres-
sure to the value of 52 ± 1.12, 79 ± 1.86 and 78.2 ± 2 mmHg,
respectively, after administration of 0.5, 1 and 2 mg/kg
tacrolimus.
The intraventricular pressure was measured to determine
the degree of left ventricular response to isoproterenol. Iso-
proterenol reduced the LVSP from 112.8 ± 2.71 mmHg
in the control group to 72.8 ± 1.38 mmHg (P < 0.001).
Figure 1 Effect of tacrolimus on electrocardiographic patterns and changes (recorded from limb lead II) in normal control, tacrolimus
alone treated group (Sham), isoproterenol alone injected (ISO), and rats treated with tacrolimus (Tac: 0.5, 1, 2 mg/kg).
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normal value in a dose-dependent manner.
Furthermore, isoproterenol treatment leads to almost
a three-fold elevation in LVEDP, which was indicative of
left ventricular dysfunction. All three doses of tacrolimus
remarkably (P < 0.01) improved the left ventricular func-
tion by lowering LVEDP from 17.6 ± 0.68 mmHg in
isoproterenol-treated rats to 10.2 ± 0.45, 6 ± 0.24 and
5.6 ± 0.22, respectively (Table 1).
Compared with the control group, the rats with left ven-
tricular dysfunction (MI group) demonstrated a reduction
in the value of left ventricular maximal and minimal rates
of pressure (LV dP/dtmax; LV dP/dtmin; P < 0.01; Figure 3)
as well as a lower rate of pressure change at a fixed
ventricular pressure (LV dP/dt/P; P < 0.05; Table 1). The
mentioned indices of myocardial contractility, along with
LVSP, were considerably improved by administration of
all three doses of tacrolimus (Figure 3). In this regard,
tacrolimus at doses of 0.5, 1 and 2 mg/kg significantly
increased LV dP/dtMax to 3702 ± 308 (P < 0.05), 4484 ±
318 (P < 0.001) and 4592 ± 333 mmHg/s (P < 0.001),
respectively, from 2712 ± 181 mmHg/s in isoproterenol
alone treated group. Tacrolimus had a similar effect on
LV dP/dtMin.
Effects of tacrolimus on the heart weight to body weight
ratio
The heart weight to body weight ratio (mg/kg) was de-
termined to evaluate the amount of heart weight gain
developed by the injection of isoproterenol (Figure 4).
Isoproterenol injection significantly increased the ratiofrom 2.58 ± 0.22 in control group to 3.94 ± 0.14 (P < 0.01).
Acute treatment with 1 mg/kg of tacrolimus resulted in a
substantial (P < 0.01) reduction in the heart to body weight
ratio in comparison to the isoproterenol alone treated rats.
Effects of tacrolimus on lipid peroxidation
To determine the lipid peroxidation, MDA levels were
measured in serum and myocardial homogenates. Both
serum and heart MDA levels were considerably increased
(P < 0.001) in isoproterenol alone treated rats in compari-
son with normal control group (Table 2). However, treat-
ment with tacrolimus significantly suppressed the rise of
MDA levels of serum and myocardium (P < 0.001; Table 2).
Histopathological examination of the cardiac tissue
In the control group, myocardial fibers were arranged
regularly with clear striations, without any damage or
necrosis in the tissue (Figure 5). Histopathological sections
of the isoproterenol alone treated hearts displayed exten-
sive hypertrophy, necrosis and increased edematous inter
muscular space. Scoring the necrosis showed that all three
doses of tacrolimus significantly prevented inflammatory
responses. Tacrolimus at doses of 0.5, 1 and 2 mg/kg re-
duced isoproterenol-induced edema and necrosis by 28%
(P < 0.05), 35% (P < 0.01) and 24% (P < 0.05), respectively
(Figure 6).
Effects of tacrolimus on the level of TNF-α in serum after
myocardial infarction
In the present study, the effects of tacrolimus on the con-
centration of TNF-α in serum of rats with isoproterenol
Figure 2 Effects of oral administration of tacrolimus (tac) on ST segment and R-amplitude (recorded from limb lead II). cP < 0.001
compared to normal controls. **P < 0.01 and ***P < 0.001 as compared to the ISO-treated group. Data are reported as mean ± SEM (n = 6).
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whether inflammatory condition in myocardium are asso-
ciated with the level of pro-inflammatory cytokines. It was
found that the level of TNF-α was profoundly increased
in the isoproterenol group in comparison to the controlTable 1 Effects of short term oral administration of tacrolimu
isoproterenol (ISO) induced myocardial infarction rats
Groups MAP ± SEM HR ± SEM
(mmHg) (bpm)
Control 79.5 ± 1.78 197.8 ± 3.05
Sham 80.4 ± 2.52 216.4 ± 6.21
ISO 37 ± 1.05c 290 ± 7.9c
ISO + tac 0.5 mg 52 ± 1.12* 247 ± 7.35*
ISO + tac 1 mg 79.8 ± 1.86*** 200.2 ± 4.84***
ISO + tac 2 mg 78.2 ± 2.06*** 212.8 ± 5.43***
aP < 0.05, cP < 0.001 compared to normal control group. *P < 0.05 and ***P < 0.001 a
(HR), left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (
are shown as mean ± SEM (n = 6).group (P < 0.001) in serum (Figure 7). It was observed that
tacrolimus alone (100 mg/kg/12 h) in the sham group had
no effect on the level of TNF-α in serum. The increased
level of TNF-α by isoproterenol was markedly decreased
by treatment with tacrolimus serum. The maximal effects (tac) on hemodynamic parameters in normal and
LVSP ± SEM LVEDP ± SEM LVdp/dt/p ± SEM
(mmHg) (mmHg) (1/sec)
112.8 ± 2.71 6.3 ± 0.21 85.2 ± 1.49
117.6 ± 4.03 5.4 ± 0.36 85.6 ± 1.52
72.8 ± 1.389c 17.6 ± 0.68c 53.4 ± 1.07a
83.4 ± 1.57 10.2 ± 0.45*** 65 ± 1.96*
120.6 ± 3.76*** 6 ± 0.24*** 86.6 ± 2.07***
117.8 ± 3.24*** 5.6 ± 0.22*** 83.4 ± 1.95***
s compared to the ISO-treated group. Mean arterial pressure (MAP), heart rate
LVEDP), left ventricular pressure changes at a fixed pressure (LV dP/dt/P). Data
Figure 3 The effect of oral administration of tacrolimus (tac) on the minimum and maximum left ventricular pressure (LVdP/dtMax,
LVdP/dtMin).
cP < 0.001 as compared to the normal control group, *P < 0.05 and ***P < 0.001 as compared to the ISO-treated group. Data are
reported as mean ± SEM (n = 6).
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tration of TNF-α was significantly reduced from 410 ±
22 pg/mL of serum to 160 ± 14 pg/mL (P < 0.001)
(Figure 7).
Discussion
Electrocardiogram (ECG) is considered the most important
clinical tool for the diagnosis of many types of myocardial
infarction, especially for detection of ST segment elevation
myocardial infarction (STEMI). Subcutaneous injection of
isoproterenol (100 mg/kg) for two consecutive days caused
ST- segment elevation and R-amplitude depression. The
elevated ST-segment implies the loss of cell membrane
function and the consequent potential difference be-
tween the ischemic and non-ischemic regions and the
depressed R-amplitude might be due to the isoproterenol-Figure 4 Effects of isoproterenol (ISO) injection as well as tacrolimus
of tissue edemathose in different groups. bP < 0.01 compared to respec
isoproterenol (ISO) treated group. Data are reported as mean ± SEM (n = 6)induced myocardial edema [14]. Tacrolimus administration
significantly amended the ECG pattern, indicating its
protective effects on cell membrane function and electrical
discharges.
Isoproterenol injection was followed by a significant
decrease in arterial pressure indices, including ventricular
contractility (LVdP/dtmax) and relaxation (LVdP/dtmin), as
well as an increase in the left ventricular end-diastolic
pressure (LVEDP). These disturbances were compatible
with the hemodynamic changes occurring in the acute
myocardial infarction.
The principal goal of post-MI therapy is to preserve the
contractility of the heart (LVdP/dtmax and LVdP/dtmin) and
to decrease the elevated LVEDP. Lower values of LVEDP
result in improved blood flow to the subendocardial tissue,
which is greatly susceptible to ischemic necrosis.(tac) on heart weight (HW) to body weight (BW) ratio as an index
tive group in healthy animals, *P < 0.05 and **P < 0.01 as compared to
.
Table 2 The effects of acute treatment with tacrolimus
(tac) on malondialdehyde (MDA) levels in the serum and
heart tissue of control and rats with myocardial
infarction
Groups (n = 6) MDA (nmol/mL serum) MDA (nmol/g tissue)
Control 5.4 ± 0.48 2.7 ± 0.08
sham 4.9 ± 0.3 2.4 ± 0.09
Isoproterenol (Iso) 13.7 ± 0.2a 5.78 ± 0.17c
Iso + tac (0.5 mg/kg) 7.8 ± 1.7*** 4.54 ± 0.12**
Iso + tac (1 mg/kg) 7.2 ± 0.6*** 2.9 ± 0.06***
Iso + tac (2 mg/kg) 4.2 ± 0.5*** 2.5 ± 0.09***
aP < 0.001, cP < 0.01 from respective control value; *P < 0.05, **P < 0.01 and
***P < 0.001 as compared with ISO-treated group. Data are expressed as mean ±
SEM (n = 6).
Figure 5 Photomicrographs of sections of rat cardiac apexes. Heart tis
cardiomyocyte necrosis and increased edematous intramuscular space. Acu
improvement. H&E (40' magnification).
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the beneficial effects of acute treatment with tacrolimus,
administered concurrently with the induction of myocar-
dial infarction, on various parameters of cardiac function.
Tacrolimus was found to effectively raise the arterial blood
pressure and myocardial contractility, along with decreas-
ing the left ventricular end diastolic pressure.
Tacrolimus had more significant protective effects on the
left ventricular function at the low dose of 1 mg/kg com-
pared with the dose of 2 mg/kg. This might be due to
the paradoxical effects of the high dose of tacrolimus
on inflammatory process and on intracellular calcium
homestasis. Tacrolimus binds to FKBP and suppresses
inflammatory responses. On the other hand, since FKBP
plays a critical role in modulating myocardial calcium
homeostasis by stabilizing ryanodine receptors, the bind-
ing may disturbs the calcium homeostasis and therefore,
reverse the protective effects of the drug [7,11]. It seemssue of a rat treated with isoproterenol (ISO) showed intensive
te treatment with tacrolimus (tac) demonstrated a marked
Figure 6 Grading of histopathological changes in the rat’s cardiac apex tissues. Grades 1, 2, 3, and 4 showed low, moderate, high and
intensive pathological changes, respectively. cP < 0.001 compared to respective group in healthy animals, *P < 0.05 and **P <0.01 as compared to
isoproterenol treated group. Data are reported as mean ± SEM (n = 6).
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pressing inflammatory responses and meanwhile, it inhibits
the stabilizing effects of FKBP on ryanodine receptors by
binding to it [17].
The importance of oxidative stress is implicated in the
pathology of myocardial infarction. There is appreciable
evidence validating the direct toxic effects of free radi-
cals on heart tissue [18]. In fact, one of the mecha-
nisms of isoproterenol-induced myocardial infarction
is to generate highly cytotoxic free radicals, as superoxide.
Malondialdehyde, a product of the oxidative degradation
of unsaturated fatty acids, is a biomarker of oxidative
stress, and the concentration increases in response to
the free radical production in myocardial infarction, and
decreases by antioxidant systems [19,20]. The results of the
present study suggest that tacrolimus possesses an in vivo
antioxidant activity. Tacrolimus administration substantially
reduced peroxylipid levels by 50 - 70% in isoproterenol-
induced myocardial infarction. This reduction may re-
late to blunted polymorphonuclear leukocyte accumula-
tion [21]. Tacrolimus treatment ameliorates oxidative stressFigure 7 The effect of acute and short term treatment with tacrolimu
concentration in serum. cP < 0.001 from respective control value; **P < 0.0
group. Data are reported as mean ± SEM (n = 6).augmentation which plays a pivotal role in the myocardial
infarction pathology.
Histopathological examination of infarcted myocardial
tissue elucidated extensive hypertrophy, subendocar-
dial necrosis, and edema. All three doses of tacrolimus
considerably attenuated the edema and necrosis in the
isoproterenol-treated heart.
The heart to body weight ratio was significantly increased
following isoproterenol injection. The heart weight gain
might be due to water absorption and increase in pro-
tein content of muscular cells. Cardiac hypertrophy is due
to increased cardiac performance. Treatment with all doses
of tacrolimus markedly reduced the heart to body weight
ratio. However, the drug was very effective at the low dose
of 1 mg/kg.
Conclusions
Limited data are available on the cardioprotective effects
of tacrolimus. However, our study finds that administra-
tion of tacrolimus, simultaneous to the myocardial in-
farction incidence, has a remarkable protective potentials (tac) at the doses of 0.5, 1 and 2 mg/kg/12 h on TNFα
1 and ***P < 0.001 as compared with isoproterenol (ISO) injected
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cardial infarction. The cardioprotective effects of acute
treatment with tacrolimus are confirmed by amending
electrocardiographic pattern, improvement of hemodynamic
and left ventricular functions, and less histopathological
damage following isoproterenol-induced myocardial in-
farction. It is proposed that tacrolimus exerts this cardi-
oprotective effects through its anti-inflammatory and
antioxidant properties. Although this study has provided a
possible new therapeutic tool for myocardial infarction,
more studies are required to elucidate the precise mechan-
ism of tacrolimus in reversing the pathogenesis of myocar-
dial infarction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
MH Carried out animals grouping and handling and the biochemical
experiments. AK Carried out the hemodynamic experiments. MG
Accompanied Mojtaba Hammami in MI induction and helped in preparing
manuscript. NM Histopathological works and interpretations. AG Supervising
and directing the project carried out the data analysis and interpretations
and prepared the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
The present study was supported by a grant from the Research Vice Chancellors
of Tabriz University of Medical Sciences; Tabriz, Iran. This article is based on a
thesis submitted for PharmD degree (No: 5/4/3419) in Faculty of Pharmacy,
Tabriz University of Medical Sciences, Tabriz, Iran.
Author details
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz
University of Medical Sciences, Tabriz, Iran. 2Student Research Committee,
Tabriz University of Medical Sciences, Tabriz, Iran.
Received: 31 March 2014 Accepted: 21 September 2014
References
1. Xie N, Zhang W, Li J, Liang H, Zhou H, Duan W, Xu X, Yu S, Zhang H, Yi D:
α-linolenic acid intake attenuates myocardial ischemia/reperfusion injury
through anti-inflammatory and anti-oxidative stress effects in diabetic
but not normal rats. Arch Med Res 2011, 42:171–181.
2. Colditz GA, Rimm EB, Giovannucci E, Stampfer MJ, Rosner B, Willett WC:
A prospective study of parental history off myocardial infarction and
coronary artery disease in men. Am J Cardiol 1991, 67:933–938.
3. Neumar RW, Browns CG, Robitaille P-ML, Altschul RA: Myocardial high
energy phosphate metabolism during ventricular fibrillation with
total circulatory arrest. Resuscitation 1990, 19:199–226.
4. Ivan Hall R, Amos Moffitt E: The effects of anaesthetics on coronary artery
blood flow and myocardial metabolism: a review of studies in animals
and man. Baillières Clin Anaesthesiol 1989, 3:27–46.
5. Bodi V, Sanchis J, Morales JM, Marrachelli VG, Nunez J, Forteza MJ, Chaustre F,
Gomez C, Mainar L, Minana G, Rumiz E, Husser O, Noguera I, Diaz A, Moratal D,
Carratala A, Bosch X, Llacer A, Chorro FJ, Viña JR, Monleon D: Metabolomic
profile of human myocardial ischemia by nuclear magnetic resonance
spectroscopy of peripheral blood serum: a translational study based on
transient coronary occlusion models. J Am Coll Cardiol 2012, 59:1629–1641.
6. Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H,
Sekikawa K, Seishima M: Improved myocardial ischemia/reperfusion injury in
mice lacking tumor necrosis factor-α. J Am Coll Cardiol 2002, 39:1229–1235.
7. Yang CH, Sheu JJ, Tsai TH, Chua S, Chang LT, Chang HW, Lee FY, Chen YL,
Chung SY, Sun CK, Leu S, Yen CH, Yip HK: Effect of tacrolimus on
myocardial infarction is associated with inflammation, ROS, MAP kinase
and Akt pathways in mini-pigs. J Atheroscler Thromb 2013, 20:9–22.8. Mazzone A, Cusa C, Mazzucchelli I, Vezzoli M, Ottini E, Pacifici R, Zuccaro P,
Falcone C: Increased production of inflammatory cytokines in patients
with silent myocardial ischemia. J Am Coll Cardiol 2001, 38:1895–1901.
9. Van Rossum H, Romijn F, Smit N, de Fijter J, Van Pelt J: Everolimus and
sirolimus antagonize tacrolimus based calcineurin inhibition via competition
for FK-binding protein 12. Biochem Pharmacol 2009, 77:1206–1212.
10. Chua S, Leu S, Sheu JJ, Lin YC, Chang LT, Kao YH, Yen CH, Tsai TH, Chen YL,
Chang HW, Sun CK, Yip HK: Intra-coronary administration of tacrolimus
markedly attenuates infarct size and preserves heart function in porcine
myocardial infarction. J Inflamm 2012, 9:21–33.
11. Su Z, Sugishita K, Li F, Ritter M, Barry W: Effects of FK506 on [Ca2+]i differ
in mouse and rabbit ventricular myocytes. J Pharmacol Exp Ther 2003,
304:334–341.
12. Yousefi K, Soraya H, Fathiazad F, Khorrami A, Hamedeyazdan S, Maleki-Dizaji
N, Garjani A: Cardioprotective effect of methanolic extract of Marrubium
vulgare L. on isoproterenol-induced acute myocardial infarction in rats.
Indian J Exp Biol 2013, 51:653–660.
13. Fathiazad F, Matlobi A, Khorrami A, Hamedeyazdan S, Soraya H, Hammami
M, Maleki-Dizaji N, Garjani A: Phytochemical screening and evaluation of
cardioprotective activity of ethanolic extract of Ocimum basilicum L.
(basil) against isoproterenol induced myocardial infarction in rats.
DARU J Pharm Sci 2012, 20:87–97.
14. Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, Garjani A, Maleki-Dizaji N:
Combined atorvastatin and coenzyme Q10 improve the left ventricular
function in isoproterenol-induced heart failure in rat. Eur J Pharmacol 2011,
666:135–141.
15. Satoh K: Serum lipid peroxide in cerebrovascular disorders determined
by a new colorimetric method. Clinica Chimica Acta 1978, 90:37–43.
16. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA: Isoproterenol-
induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989,
65:657–670.
17. Shawn D, St. P, Adyr AM, David CM: Effects of tacrolimus on ischemia-
reperfusion injury. Liver Transpl 2003, 9:105–116.
18. Rona G: Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985, 7:291–306.
19. Radovanovic S, Savic-Radojevic A, Pljesa-Ercegovac M, Djukic T, Suvakov S,
Krotin M, Simic DV, Matic M, Radojicic Z, Pekmezovic T, Simic T: Markers of
oxidative damage and antioxidant enzyme activities as predictors of
morbidity and mortality in patients with chronic heart failure. J Card Fail
2012, 18:493–501.
20. Ho E, Karimi Galougahi K, Liu C-C, Bhindi R, Figtree GA: Biological markers
of oxidative stress: applications to cardiovascular research and practice.
Redox Biol 2013, 1:483–491.
21. Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, Arlotta M, Minutoli
L, Quartarone C, Ferlito M, Caputi AP: Tacrolimus limits
polymorphonuclear leucocyte accumulation and protects against
myocardial ischaemia–reperfusion injury. J Mol Cell Cardiol 2000, 32:429–440.
doi:10.1186/s40199-014-0068-3
Cite this article as: Khorrami et al.: Tacrolimus ameliorates functional
disturbances and oxidative stress in isoproterenol-induced myocardial
infarction. DARU Journal of Pharmaceutical Sciences 2014 22:68.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
